SAH-SOS1A TFA

SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity ( EC 50 =106-175 nM). SAH-SOS1A TFA directly and independently blocks nuc Appearance:Solid IC50& Target:KRAS-SOS1 KRas G12C 140 nM (EC 50 ) KRas G12D 109 nM (EC 50 ) KRas G12V 154 nM (EC 50 ) KRas G12S 155 nM (EC 50 ) KRas Q61H 175 nM (EC 50 ) K-Ras WT 106 nM (EC 50 ) In Vitro:SAH-SOS1A TFA (0.625-40 μM; 24 hours) dose-responsively impairs the viability of cancer cells bearing G12D, G12C, G12V, G12S, G13D, and Q61H mutations with IC50 values in the 5- to 15-μM range. Cancer cells expressing wild-type KRAS, such as HeLa and Colo In Vivo:SAH-SOS1A (0.2 μL of 10 mM solution; injection; 48 hours; abdomens of D. melanogaster Ras85D V12 /ActinGS) treatment notably decreases the phosphorylation state of ERK1/2. MCE has not independently confirmed the accuracy of these methods. They are fo Biological Activity:SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity ( EC 50 =106-175 nM). SAH-SOS1A TFA directly and independently blocks nuc

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet